Literature DB >> 2495016

Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours.

P Shah1, P H van der Meide, T Borman, N Schroeder, J M Bliss, R C Coombes.   

Abstract

We have used the nitrosomethylurea-induced rat mammary tumour model to study the effects of parenteral administration of human recombinant tumour necrosis factor (rHu-TNF) and rat gamma interferon (IFN-gamma). An inbred strain of tumour bearing female Ludwig/Wistar/Olac rats were randomised to either treatment or control groups. Two independent studies showed that combined treatment with rHu-TNF and rat IFN-gamma induced significant tumour regression over 4 weeks (P = 0.004, P = 0.005 respectively). Treatment with either rHu-TNF or rat IFN-gamma given individually did not affect the overall rate of tumour growth (P = 0.157 and 0.40 respectively) although an initial reduction in tumour size was observed during the first few days after injection. Measurement of circulating oestradiol levels in groups in which maximum tumour regression was observed showed no statistically significant difference when compared to the control group. Similarly, measurement of oestrogen receptor content showed no statistically significant difference between rHu-TNF-gamma or rat-IFN-gamma treatment or combined treatment of rHu-TNF and IFN-gamma with the control group. We conclude from these observations that combined therapy with rHu-TNF and rat IFN-gamma may prove to be useful new forms of treatment for human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495016      PMCID: PMC2246997          DOI: 10.1038/bjc.1989.42

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons.

Authors:  F R Balkwill; A Lee; G Aldam; E Moodie; J A Thomas; J Tavernier; W Fiers
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

2.  Improved sensitivity in the measurement of estrogen receptor in human breast cancer.

Authors:  W L McGuire; M DeLaGarza
Journal:  J Clin Endocrinol Metab       Date:  1973-12       Impact factor: 5.958

3.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

4.  Macrophages as a source of tumoricidal activity (tumor-necrotizing factor).

Authors:  D N Männel; R N Moore; S E Mergenhagen
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

5.  N-nitrosomethylurea as mammary gland carcinogen in rats.

Authors:  P M Gullino; H M Pettigrew; F H Grantham
Journal:  J Natl Cancer Inst       Date:  1975-02       Impact factor: 13.506

6.  Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response.

Authors:  J R Wilkinson; J C Williams; D Singh; P E Goss; D Easton; R C Coombes
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

7.  Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

Authors:  M Dowsett; P E Goss; T J Powles; G Hutchinson; A M Brodie; S L Jeffcoate; R C Coombes
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

8.  Growth factor expression in normal, benign, and malignant breast tissue.

Authors:  M T Travers; P J Barrett-Lee; U Berger; Y A Luqmani; J C Gazet; T J Powles; R C Coombes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-11

9.  Effects of growth factors on the antiproliferative activity of tumor necrosis factors.

Authors:  B J Sugarman; G D Lewis; T E Eessalu; B B Aggarwal; H M Shepard
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

10.  Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.

Authors:  A A Creasey; M T Reynolds; W Laird
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

View more
  2 in total

1.  The antitumour activity of the interferon inducer bropirimine is partially mediated by endogenous tumour necrosis factor alpha.

Authors:  M Scheringa; J N IJzermans; J Jeekel; R L Marquet
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Vascular-targeted TNFα and IFNγ inhibits orthotopic colorectal tumor growth.

Authors:  Jing Shen; Zhi Jie Li; Long Fei Li; Lan Lu; Zhan Gang Xiao; William Ka Kei Wu; Lin Zhang; Ming Xing Li; Wei Hu; Kam Ming Chan; Chi Hin Cho
Journal:  J Transl Med       Date:  2016-06-24       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.